Artivion (AORT) Scheduled to Post Earnings on Thursday

Artivion (NYSE:AORT) is set to post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect Artivion to post earnings of $0.03 per share for the quarter. Artivion has set its FY 2024 guidance at EPS.Investors that wish to register for the company’s conference call can do so using this link.

Artivion (NYSE:AORT) last posted its earnings results on Thursday, August 8th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.04. Artivion had a negative net margin of 2.22% and a positive return on equity of 3.81%. The company had revenue of $98.02 million for the quarter, compared to analysts’ expectations of $97.70 million. On average, analysts expect Artivion to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Artivion Price Performance

Shares of AORT opened at $26.64 on Thursday. The firm has a 50-day simple moving average of $25.96 and a two-hundred day simple moving average of $24.76. The stock has a market cap of $1.12 billion, a PE ratio of -127.95 and a beta of 1.74. Artivion has a 1-year low of $12.47 and a 1-year high of $29.24. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.63 and a quick ratio of 4.04.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on AORT. Needham & Company LLC reissued a “buy” rating and issued a $30.00 target price on shares of Artivion in a research report on Friday, September 27th. Oppenheimer raised their target price on Artivion from $25.00 to $30.00 and gave the company an “outperform” rating in a report on Friday, August 9th. JMP Securities initiated coverage on shares of Artivion in a research report on Wednesday, October 23rd. They set an “outperform” rating and a $33.00 price target on the stock. Finally, Stifel Nicolaus lifted their price objective on shares of Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a report on Friday, September 13th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $30.60.

Insider Transactions at Artivion

In related news, CAO Amy Horton sold 12,430 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total value of $325,417.40. Following the transaction, the chief accounting officer now owns 139,989 shares of the company’s stock, valued at $3,664,912.02. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, SVP Jean F. Holloway sold 3,167 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $26.55, for a total value of $84,083.85. Following the completion of the sale, the senior vice president now directly owns 161,932 shares of the company’s stock, valued at $4,299,294.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Amy Horton sold 12,430 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total value of $325,417.40. Following the transaction, the chief accounting officer now owns 139,989 shares in the company, valued at $3,664,912.02. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 37,109 shares of company stock valued at $951,935. 8.10% of the stock is currently owned by corporate insiders.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.